Verastem Stock (NASDAQ:VSTM)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$3.96

52W Range

$2.10 - $14.22

50D Avg

$3.23

200D Avg

$6.37

Market Cap

$168.68M

Avg Vol (3M)

$819.14K

Beta

0.14

Div Yield

-

VSTM Company Profile


Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

73

IPO Date

Jan 27, 2012

Website

VSTM Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Sale of COPIKTRA license and related assets$2.60M--
Copiktra license and related assets-$1.45M-
Government rebates and other incentives-$67.00K-
Trade discounts and allowances-$23.00K-
Returns-$31.00K-
Product Revenue And Allowances Returns--$31.00K
Product Revenue Reserves And Allowances Trade Discounts And Allowances--$23.00K
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees--$2.08M
Product Revenue Reserves And Allowances Government Rebates And Other Incentives--$67.00K

Fiscal year ends in Dec 23 | Currency in USD

VSTM Financial Summary


Dec 23Dec 22Dec 21
Revenue-$2.60M$2.05M
Operating Income$-92.08M$-72.94M$-61.41M
Net Income$-87.37M$-73.85M$-81.10M
EBITDA$-92.08M$-71.67M$-61.23M
Basic EPS$-3.96$-4.58$-5.58
Diluted EPS$-3.96$-4.58$-5.58

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 19Oct 29, 19 | 8:21 PM
Q2 19Aug 02, 19 | 12:48 AM
Q1 19May 09, 19 | 10:56 PM

Peer Comparison


TickerCompany
INFIInfinity Pharmaceuticals, Inc.
ACRXTalphera, Inc.
TRVNTrevena, Inc.
KPTIKaryopharm Therapeutics Inc.
VKTXViking Therapeutics, Inc.